Long COVID-19 syndrome, or post-acute sequelae of SARS-CoV-2 infection (PASC), is a complex condition with persistent neurological and gastrointestinal (GI) symptoms. Emerging evidence highlights the role of gut-brain axis (GBA) dysfunction, driven by gut dysbiosis, neuroinflammation, and vagus nerve impairment. SARS-CoV-2 alters gut microbiota, reducing beneficial bacteria and increasing intestinal permeability, leading to systemic inflammation that exacerbates cognitive and GI symptoms. Neuroinflammatory processes disrupt neurotransmitter balance, contributing to brain fog, mood disorders, and neurodegeneration. Targeted therapies, including probiotics, fecal microbiota transplantation (FMT), and vagus nerve stimulation (VNS), offer potential for symptom relief. Understanding GBA disruption in Long COVID could pave the way for novel treatments.
Introduction Long COVID-19 syndrome, officially termed post-acute sequelae of SARS-CoV-2 infection (PASC), represents a complex, multi-system condition affecting individuals months after recovering from an acute SARS-CoV-2 infection. The syndrome is characterized by persistent symptoms including fatigue, brain fog, gastrointestinal (GI) disturbances, anxiety, and depression. Many of these manifestations suggest a disruption of the gut-brain axis (GBA), a bidirectional communication system linking the central nervous system (CNS) and the gastrointestinal tract via neural, immune, and endocrine pathways. Recent research has highlighted the long-term implications of SARS-CoV-2 infection on gut microbiota, neuroinflammation, and immune dysregulation, all of which contribute to the development and persistence of Long COVID symptoms. The gut-brain axis plays a vital role in maintaining hlongtermostasis by regulating neurotransmitter production, immune responses, and intestinal barrier integrity.
The emerging evidence suggests that SARS-CoV-2 induces gut dysbiosis, disrupts vagus nerve signaling, and triggers persistent inflammation, contributing to both cognitive and digestive dysfunction in affected individuals. Understanding how COVID-19 impacts the gut-brain axis is essential for developing effective therapeutic interventions aimed at restoring microbial balance, modulating immune responses, and improving neurological and gastrointestinal health. PATHOPHYSIOLOGY OF LONG COVID AND THE GUT- BRAIN AXIS Gut Dysbiosis and Microbial Alterations The composition of the gut microbiota is significantly altered in individuals suffering from Long COVID, a condition referred to as gut dysbiosis. Studies have demonstrated a marked depletion of beneficial bacterial species such as Faecalibacterium prausnitzii, Bifidobacterium, and Akkermansia muciniphila, all of which play crucial roles in maintaining gut integrity and modulating immune responses.
Concurrently, there is an increase in pathogenic bacteria, including Enterobacteriaceae, Clostridium difficile, and Escherichia coli, which contribute to intestinal inflammation, increased gut permeability, and systemic immune activation. The loss of beneficial bacteria also leads to a reduction in the production of short-chain fatty acids (SCFAs) such as butyrate, which are essential for maintaining the intestinal barrier and regulating neuroimmune communication. The persistence of gut dysbiosis in Long COVID patients correlates with the severity of neurological and GI symptoms, suggesting a direct link between microbial imbalance and prolonged post-viral illness [1,2]. Neuroinflammation and Vagus Nerve Dysfunction The vagus nerve plays a critical role in the gut-brain axis by facilitating bidirectional communication between the enteric nervous system and the brain.
Long COVID is associated with vagus nerve dysfunction, which may contribute to persistent autonomic dysregulation, fatigue, and cognitive impairment. Elevated levels of pro-inflammatory cytokines such as IL-6, TNF-α, and IFN-γ have been detected in Long COVID patients, contributing to chronic neuroinflammation and microglial activation. This inflammatory state impairs vagal tone and alters neurotransmitter synthesis, particularly affecting serotonin, dopamine, and gamma-aminobutyric acid (GABA) levels, leading to symptoms such as brain fog, anxiety, and mood disorders. Vagus nerve dysfunction also disrupts normal gut motility, contributing to gastrointestinal symptoms such as diarrhea, constipation, and irritable bowel syndrome (IBS)-like conditions commonly reported in Long COVID patients [3,4]. Persistent Gastrointestinal Symptoms and Gut-Brain Disorders Gastrointestinal disturbances are among the most common complaints in Long COVID patients.
Symptoms such as chronic diarrhea, bloating, nausea, and abdominal pain have been observed in individuals months after the resolution of acute infection. These symptoms may be driven by post-viral enteric nervous system dysfunction and gut dysbiosis. Increased intestinal permeability, often referred to as “leaky gut,” allows bacterial endotoxins such as lipopolysaccharides (LPS) to enter the bloodstream, triggering a systemic inflammatory response that further exacerbates neurological and gastrointestinal symptoms. The link between post-infectious IBS and Long COVID suggests that SARS-CoV-2 infection can induce long-term alterations in gut function similar to those seen after other viral and bacterial infections [5]. NEUROLOGICAL DISORDERS AND THE GUT-BRAIN AXIS IN LONG COVID The neurological complications of Long COVID-19 syndrome are among the most debilitating and persistent symptoms reported by patients.
These include brain fog, cognitive impairment, memory loss, headaches, mood disorders, neuropathic pain, and an increased risk of neurodegenerative diseases. While the precise mechanisms underlying these neurological manifestations are still being explored, emerging evidence suggests a strong link between gut dysbiosis, neuroinflammation, and disrupted gut-brain communication. The gut-brain axis (GBA) is a bidirectional signaling network that connects the enteric nervous system (ENS) with the central nervous system (CNS) through the vagus nerve, immune mediators, and microbial metabolites. Dysregulation of this axis following SARS-CoV-2 infection has been implicated in neuroinflammatory responses, neurotransmitter imbalances, and mitochondrial dysfunction, contributing to the neurological symptoms seen in Long COVID patients. This section explores the pathophysiology of Long COVID-related neurological disorders, highlighting the role of gut microbiota, systemic inflammation, and neurodegeneration in persistent cognitive and neuropsychiatric symptoms [5, 6].
Brain Fog, Cognitive Impairment, and Neurodegeneration One of the most debilitating aspects of Long COVID is cognitive impairment, often described as “brain fog,” which manifests as memory difficulties, reduced concentration, and mental fatigue. Recent studies suggest that gut microbiota imbalance contributestoneuroinflammation,disruptingnormalcognitive processing. The depletion of SCFA-producing bacteria affects microglial regulation, leading to sustained neuroinflammation and impaired synaptic plasticity. Evidence also suggests that Long COVID may accelerate neurodegenerative processes, increasing the risk of conditions such as Alzheimer’s and Parkinson’s disease. Chronic neuroinflammation, oxidative stress, and mitochondrial dysfunction have been implicated in the progression of these disorders, making the gut-brain connection a potential therapeutic target for reducing neurodegenerative risk in Long COVID patients [6].
THERAPEUTIC STRATEGIES TARGETING THE GUT- BRAIN AXIS IN LONG COVID Probiotics, Prebiotics, and Postbiotics Restoring gut microbiota balance is a promising strategy for mitigating Long COVID symptoms. Probiotic supplementation with Lactobacillus and Bifidobacterium strains has been shown to improve gut barrier integrity, reduce systemic inflammation, and enhance serotonin and GABA production, thereby improving mood and cognitive function. Prebiotics, such as inulin and resistant starches, promote the growth of beneficial bacteria, while postbiotics, particularly butyrate supplements, provide anti-inflammatory benefits [7]. Fecal Microbiota Transplantation (FMT) and Gut-Directed Therapies Fecal microbiota transplantation (FMT) has emerged as a potential treatment for severe gut dysbiosis and persistent GI symptoms in Long COVID patients. Early clinical trials suggest that FMT can restore microbial diversity, reduce gut permeability, and alleviate neuroinflammation, making it a promising intervention for gut-brain axis dysfunction [8].
Other gut-directed therapies, including phytochemicals such as curcumin and resveratrol, have shown neuroprotective and anti-inflammatory properties that could benefit Long COVID patients. Vagus Nerve Stimulation (VNS) and Neuromodulation Given the role of the vagus nerve in modulating the gut-brain axis, non-invasive vagus nerve stimulation (VNS) has been proposed as a novel therapeutic approach for Long COVID. Studies indicate that VNS can reduce neuroinflammation, improve autonomic regulation, and enhance gut motility, making it a viable option for patients suffering from both neurological and gastrointestinal symptoms [9].
Conclusion Long COVID-19 syndrome has profound implications for gut-brain axis function, involving microbial dysbiosis, neuroinflammation, immune dysregulation, and mitochondrial dysfunction. Targeted therapies such as probiotics, prebiotics, FMT, vagus nerve stimulation, and gut-directed interventions offer promising strategies for restoring gut and neurological health. Future research should focus on developing microbiome-based diagnostic tools and personalized interventions for Long COVID patients. Understanding the gut-brain axis in Long COVID could pave the way for more effective treatments for post-viral syndromes and neuroinflammatory conditions.
REFERENCES
1. IqbalNT,KhanH,Khalid A,MahmoodSF,NasirN.Chronic inflammation in post-acute sequelae of COVID-19 modulates gut microbiome: A review of literature on COVID-19 sequelae and gut dysbiosis. Mol Med Rep. 2025;[Epub ahead of print]. Available from: https://link. springer.com/article/10.1186/s10020-024-00986-6.
2. Masamura Y, Kubo R, Midorikawa Y, Nakamura M. Gut microbiota and post-viral immune dysregulation in Long COVID: A review. J Microbiota Food Health. 2024;43(4):115-128. Available from: https://www.jstage. jst.go.jp/article/bmfh/43/4/43_2023-049/_pdf.
3. Talkington GMG, Kolluru P, Gressett TE, Sanders RD. Neurological sequelae of long COVID: A comprehensive review of diagnostic imaging, underlying mechanisms, and potential therapeutics. Front Neurol. 2025;146(12):122-140. Available from: https://www. frontiersin.org/journals/neurology/articles/10.3389/ fneur.2024.1465787/full.
4. Chey WD, Almario CV, Choi SY, Moszkowski R, Barba E. Gut-brain interactions in long COVID: A comprehensive analysis of microbiota changes and functional GI disorders.NeurogastroenterolMotil.2025;37(2):e70020. Available from: https://onlinelibrary.wiley.com/doi/ abs/10.1111/nmo.70020.
5. Warunek A, Gronowicz G, Wanat J, Nowak P. Irritable bowel syndrome: An underestimated consequence of post-acute COVID-19. J Educ Health Sci. 2025;15(3):212- 230. Available from: https://apcz.umk.pl/JEHS/article/ view/59072.
6. LinT,ZhangY,WangJ,XuH.Gutmicrobiotadysregulation and neuroinflammation in post-COVID-19 cognitive dysfunction: Emerging evidence. Front Cell Infect Microbiol. 2025;154(2):289-305. Available from: https:// www.frontiersin.org/journals/cellular-and-infectionmicrobiology/articles/10.3389/fcimb.2025.1541881/full.
7. Yao J, Li F, Wang S, Zhao L. Role of probiotics and prebiotics in managing post-COVID-19 gastrointestinal dysfunction: A systematic review. Front Med. 2025;156(8):302-319. Available from: https://www. frontiersin.org/journals/medicine/articles/10.3389/ fmed.2025.1569664/full.
8. McGuinness A, Whitehead J, Patterson E, O’Sullivan O, Cotter PD. Fecal microbiota transplantation and gut-directed interventions for Long COVID: Current evidence and future directions. OSF Preprints. 2024; Available from: https://osf.io/xwm2r/resources.
9. Dodero VI, Morre SA, Behzadi P. The gut microbiotaimmune-brain axis: Its role in post-viral neuroimmune disorders and emerging therapeutic interventions. Front Immunol. 2024;153(5):422-439. Available from: https://www.frontiersin.org/journals/immunology/ articles/10.3389/fimmu.2024.1536258/full.